Dracen Pharmaceuticals

Dracen Pharmaceutical is a private pharmaceutical company developing cancer therapies that target glutamine metabolism and modulate the tumor microenvironment. The company's lead candidate, sirpiglenastat (DRP-104), is a glutamine inhibitor being studied for advanced solid tumors and non-small cell lung cancer, including in combination with checkpoint inhibitors.